In patients with Systemic Lupus Erythematosus, CD4+ T cells are overactive, resulting in the overwhelming production of autoantibodies. These autoantibodies then attack healthy tissue and organs instead of foreign invaders. The intravenous targeted two-drug combo therapy will effectively normalize T cell metabolism to prevent the overproduction of autoantibodies. A combination of metformin and 2-deoxy-D-glucose are placed inside the aqueous solution core of a liposome, a nanoparticle that serves as a drug delivery vehicle. The surface of the liposome is surrounded by monoclonal antibodies, in which their targeting abilities allow the therapy to travel through the bloodstream until it finds and binds to CD4 and gp96 proteins on the surface of a T cell. By excluding a cytotoxic agent, the monoclonal antibodies will not destroy it. After binding to the cell, the lipid bilayer of the liposome fuses with the cell membrane, releasing the drugs into its interior. They will then work to slow down glucose and mitochondrial metabolism. This normalization will reduce autoantibody production, preventing attacks on healthy tissue. Instead of simply treating symptoms of lupus, the targeted two-drug combo therapy will target the potential cause of the disease, creating a more efficient and reliable treatment.